WO2000012705A3 - Methods for improving the function of heterologous g protein-coupled receptors - Google Patents

Methods for improving the function of heterologous g protein-coupled receptors Download PDF

Info

Publication number
WO2000012705A3
WO2000012705A3 PCT/US1999/020013 US9920013W WO0012705A3 WO 2000012705 A3 WO2000012705 A3 WO 2000012705A3 US 9920013 W US9920013 W US 9920013W WO 0012705 A3 WO0012705 A3 WO 0012705A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
methods
coupled receptors
heterologous
improving
Prior art date
Application number
PCT/US1999/020013
Other languages
French (fr)
Other versions
WO2000012705A9 (en
WO2000012705A2 (en
Inventor
Mark Henry Pausch
Jurgen Wess
Original Assignee
Mark Henry Pausch
Jurgen Wess
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark Henry Pausch, Jurgen Wess filed Critical Mark Henry Pausch
Priority to CA002344591A priority Critical patent/CA2344591A1/en
Priority to EP99944035A priority patent/EP1123391A2/en
Priority to US09/786,033 priority patent/US7094593B1/en
Priority to AU57011/99A priority patent/AU756244B2/en
Priority to JP2000567692A priority patent/JP2002523091A/en
Publication of WO2000012705A2 publication Critical patent/WO2000012705A2/en
Publication of WO2000012705A9 publication Critical patent/WO2000012705A9/en
Publication of WO2000012705A3 publication Critical patent/WO2000012705A3/en
Priority to US11/708,333 priority patent/US20080032317A1/en
Priority to US11/984,615 priority patent/US20080153124A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention relates to mutant G protein-coupled receptors with improved G-protein coupling and receptor response, yeast cells expressing such receptors, vectors useful for making such cells, and methods of making and using same.
PCT/US1999/020013 1998-09-01 1999-09-01 Methods for improving the function of heterologous g protein-coupled receptors WO2000012705A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002344591A CA2344591A1 (en) 1998-09-01 1999-09-01 Methods for improving the function of heterologous g protein-coupled receptors
EP99944035A EP1123391A2 (en) 1998-09-01 1999-09-01 Methods for improving the function of heterologous g protein-coupled receptors
US09/786,033 US7094593B1 (en) 1998-09-01 1999-09-01 Method for improving the function of heterologous G protein-coupled receptors
AU57011/99A AU756244B2 (en) 1998-09-01 1999-09-01 Methods for improving the function of heterologous G protein-coupled receptors
JP2000567692A JP2002523091A (en) 1998-09-01 1999-09-01 Method for altering the function of a heterologous G protein-coupled receptor
US11/708,333 US20080032317A1 (en) 1998-09-01 2007-02-21 Methods for improving the function of heterlogous G protein-coupled receptors
US11/984,615 US20080153124A1 (en) 1998-09-01 2007-11-20 Methods for improving the function of heterlogous G protein-coupled receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9870498P 1998-09-01 1998-09-01
US60/098,704 1998-09-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US60098704 Division 1998-09-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US47310906A Division 1998-09-01 2006-06-23

Publications (3)

Publication Number Publication Date
WO2000012705A2 WO2000012705A2 (en) 2000-03-09
WO2000012705A9 WO2000012705A9 (en) 2000-07-13
WO2000012705A3 true WO2000012705A3 (en) 2000-10-05

Family

ID=22270543

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/020011 WO2000012704A2 (en) 1998-09-01 1999-09-01 Enhanced functional expression of g protein-coupled receptors
PCT/US1999/020013 WO2000012705A2 (en) 1998-09-01 1999-09-01 Methods for improving the function of heterologous g protein-coupled receptors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020011 WO2000012704A2 (en) 1998-09-01 1999-09-01 Enhanced functional expression of g protein-coupled receptors

Country Status (5)

Country Link
EP (2) EP1112359A2 (en)
JP (2) JP2002523090A (en)
AU (2) AU756244B2 (en)
CA (2) CA2343046A1 (en)
WO (2) WO2000012704A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
JP2004500843A (en) * 2000-04-24 2004-01-15 ワイエス Transgenic animals
AU2002214855A1 (en) * 2000-10-26 2002-05-06 The University Of British Columbia A functional assay for g-protein-coupled receptors based on insect cells
AU2002210982A1 (en) * 2000-11-01 2002-05-15 Yamanouchi Pharmaceutical Co..Ltd. Method of screening antiplatelet
US7163800B2 (en) 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US7018812B2 (en) 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
DE10056899A1 (en) 2000-11-16 2002-05-29 Aventis Pharma Gmbh New promoter from Saccharomyces cerevisiae YNL279W gene, useful e.g. for identifying modulators of G protein-coupled receptors, is responsive to pheromone alpha
AU2002228844A1 (en) * 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
GB0030038D0 (en) * 2000-12-08 2001-01-24 Univ Warwick Yeast-based assay
US7279324B2 (en) 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
EP1336655A1 (en) * 2002-01-12 2003-08-20 Aventis Pharma Deutschland GmbH Method of identifying protein CAMS (constitutively active mutants)
DE10233516A1 (en) * 2002-07-23 2004-02-12 Aventis Pharma Deutschland Gmbh Cellular method for identifying modulators of target molecules, useful in screening for pharmaceuticals, from effects of test compounds on both cell growth and reporter expression
WO2006104254A1 (en) * 2005-03-29 2006-10-05 Bio-Energy Corporation Method for screening of receptor-binding substance
CA2605228A1 (en) 2005-04-27 2007-03-08 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
EP2369341A3 (en) 2006-04-11 2012-01-04 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
EA015129B1 (en) 2007-01-04 2011-06-30 Прозидион Лимитед Piperidine gpcr agonists
AR064735A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
PE20081849A1 (en) 2007-01-04 2009-01-26 Prosidion Ltd PIPERIDIN-4-IL-PROPOXY-BENZAMIDE DERIVATIVES AS GPCR AGONISTS
CA2681415C (en) * 2007-03-22 2020-11-03 Heptares Therapeutics Limited Mutant g-protein coupled receptors and methods for selecting them
US20100286112A1 (en) 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
JP7422498B2 (en) * 2019-07-25 2024-01-26 芳武 村山 Peptides, cell migration inhibitors, cell invasion inhibitors, cancer cell metastasis inhibitors, and pharmaceuticals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021925A1 (en) * 1994-02-14 1995-08-17 American Cyanamid Company Heterologous g protein coupled receptors expressed in yeast, their fusion with g proteins and use thereof in bioassay
WO1996000739A1 (en) * 1994-06-29 1996-01-11 Merck & Co., Inc. Modified g-protein coupled receptors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255089B1 (en) * 1997-02-27 2001-07-03 Albany Medical College Constitutively activated serotonin receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021925A1 (en) * 1994-02-14 1995-08-17 American Cyanamid Company Heterologous g protein coupled receptors expressed in yeast, their fusion with g proteins and use thereof in bioassay
WO1996000739A1 (en) * 1994-06-29 1996-01-11 Merck & Co., Inc. Modified g-protein coupled receptors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLUEML K ET AL: "FUNCTIONAL ROLE OF A CYTOPLASMIC AROMATIC AMINO ACID IN MUSCARINIC RECEPTOR-MEDIATED ACTIVATION OF PHOSPHOLIPASE C", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 269, no. 15, 15 April 1994 (1994-04-15), pages 11537 - 11541, XP002911766, ISSN: 0021-9258 *
J. WESS ET AL: "Identification of a small intracellular region of the muscarinic m3 receptor as a determinant of selective coupling to PI turnover", FEBS LETTERS., vol. 258, no. 1, November 1989 (1989-11-01), AMSTERDAM NL, pages 133 - 136, XP002135334 *
O. MORO ET AL: "Serine-and Threonine-rich Domain regulates internalization of muscarinic cholinergic Receptors", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 268, no. 10, 5 April 1993 (1993-04-05), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US, pages 6862 - 6865, XP002135333, ISSN: 0021-9258 *
PAUSCH M H ET AL: "HETEROLOGOUS G PROTEIN-COUPLED RECEPTORS EXPRESSED IN SACCHAROMYCES CEREVISIAE: METHODS FOR GENETIC ANALYSIS AND LIGAND IDENTIFICATION", IDENTIFICATION AND EXPRESSION OF G-PROTEIN-COUPLED RECEPTORS, 26 May 1999 (1999-05-26), Edited by Kevin R. Lynch ISBN 0-471-19493-X. Wiley Liss, INC., pages 196 - 212, XP000869632 *
PAUSCH M H: "G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery", TRENDS IN BIOTECHNOLOGY,GB,ELSEVIER PUBLICATIONS, CAMBRIDGE, vol. 15, no. 12, 1 December 1997 (1997-12-01), pages 487 - 494, XP004097426, ISSN: 0167-7799 *
SCHEER A ET AL: "CONSTITUTIVELY ACTIVE G PROTEIN-COUPLED RECEPTORS: POTENTIAL MECHANISMS OF RECEPTOR ACTIVATION", JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH,US,MARCEL DEKKER, NEW YORK, NY, vol. 17, no. 1/03, 1997, pages 57 - 73, XP000867531, ISSN: 1079-9893 *
WESS J: "G protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition", FASEB JOURNAL,US,FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, vol. 11, no. 5, April 1997 (1997-04-01), pages 346 - 354, XP002121229, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
EP1112359A2 (en) 2001-07-04
JP2002523091A (en) 2002-07-30
WO2000012704A9 (en) 2000-06-08
AU756244B2 (en) 2003-01-09
JP2002523090A (en) 2002-07-30
WO2000012705A9 (en) 2000-07-13
WO2000012705A2 (en) 2000-03-09
CA2344591A1 (en) 2000-03-09
WO2000012704A2 (en) 2000-03-09
EP1123391A2 (en) 2001-08-16
WO2000012704A3 (en) 2000-11-30
AU5701199A (en) 2000-03-21
AU5700999A (en) 2000-03-21
CA2343046A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
WO2000012705A3 (en) Methods for improving the function of heterologous g protein-coupled receptors
WO2000031258A3 (en) Human orphan g protein-coupled receptors
WO2001036473A3 (en) Human g protein-coupled receptors
WO2001048015A3 (en) G protein-coupled receptors
WO2001062797A3 (en) G protein-coupled receptors
WO2000022131A3 (en) Non-endogenous, constitutively activated human g protein-coupled receptors
EP1162264A3 (en) Chimeric hormone receptor
WO2001081408A3 (en) G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
WO2002072605A3 (en) Expression technology for proteins containing a hybrid isotype antibody moiety
AUPP525198A0 (en) Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
WO1998044141A3 (en) Insect expression vectors
WO2000049416A3 (en) Receptor assay for detecting an effect test compounds have on a particular membrane receptor
WO2000050563A3 (en) G protein-coupled receptor resembling galanin receptors
WO2001066750A3 (en) G protein-coupled receptors
WO2003000893A3 (en) Nucleic acids encoding g protein-coupled receptors
WO2001077330A3 (en) G protein-coupled receptors
WO2001067106A8 (en) Identification of g protein-coupled receptor ligands and modulators
WO2000011204A3 (en) Homer interacting proteins
EP0950710A3 (en) Cells expressing a chimera receptor and their uses
AU5999399A (en) Novel g protein-coupled receptor protein and dna thereof
WO1999033973A3 (en) Cloned octapamine-receptor-producing cells
WO2001062924A3 (en) Human g protein-coupled receptors
WO2001081410A3 (en) G protein-coupled receptors
AU4169499A (en) Novel g protein-coupled receptor protein, dna and use thereof
WO2001077175A3 (en) G protein-coupled receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2344591

Country of ref document: CA

Ref country code: CA

Ref document number: 2344591

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 567692

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 57011/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999944035

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09786033

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999944035

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 57011/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999944035

Country of ref document: EP